How Valeant Tripled Prices, Doubled Sales of Flatlining Drug
- Wellbutrin antidepressant gets new life with free co-pays
- List price increased 11 times since 2014 to $17,000 a year
Why Schiller as Interim CEO Is Good for Valeant
This article is for subscribers only.
No wonder investors once loved Michael Pearson. In short order, he managed to double sales of Wellbutrin XL, the popular antidepressant, even though far cheaper generics were out there.
But behind that move is an untold story that illustrates how Pearson and his controversial company, Valeant Pharmaceuticals International Inc., vaulted to seemingly unimaginable heights before falling back to Earth.